ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

July 27, 2001

Letters: Broder Response To Waxman Called Political Back-Pedaling

February 11, 1994

FDA Encourages Study Of Gender Differences

August 6, 1993

In Brief: Newell Tells Advisory Committee It Isn’t a Lobbying Group, “Accept What We Give You”

April 8, 1977

In Brief: Benacerraf, Snell, Dausset Win Nobel Prize; AACE Seeks Increase In Clinical Education Funds

October 17, 1980

Caterpillar In. Benefits Plan To Cover Entry On BMT trials

June 14, 1996